Komori
ASKA Pharmaceutical Holdings (4886) · InitiativeFirst stated

Sales Rights Agreement for an OTC Oral Contraceptive

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Acquisition of Marketing Rights for an OTC Oral Contraceptive and Commercialization PartnershipA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「OTC経口避妊薬 販売権の被許諾」

    ラボラトワール エイチアールエー ファーマ、ペリーゴ サプライチェーン インターナショナル、第一三共ヘルスケア株式会社とのOTC経口避妊薬の販売権許諾契約を初めて記載している。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.